{"protocolSection":{"identificationModule":{"nctId":"NCT00482014","orgStudyIdInfo":{"id":"9031"},"secondaryIdInfos":[{"id":"H3E-US-S047","type":"OTHER","domain":"Eli Lilly and Company"}],"organization":{"fullName":"Eli Lilly and Company","class":"INDUSTRY"},"briefTitle":"A Study of Pemetrexed Plus Carboplatin, or Pemetrexed Plus Cisplatin With Radiation Therapy Followed by Pemetrexed in Patients With Inoperable Non-Small-Cell Lung Cancer","officialTitle":"Phase 1/2 Study of Pemetrexed (Alimta) Plus Carboplatin, or Pemetrexed Plus Cisplatin With Concurrent Radiation Therapy Followed by Every-21-Day Pemetrexed Consolidation in Patients With Favorable-Prognosis Inoperable Stage IIIA/B Non-Small-Cell Lung Cancer (NSCLC)"},"statusModule":{"statusVerifiedDate":"2012-10","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2007-05"},"primaryCompletionDateStruct":{"date":"2011-10","type":"ACTUAL"},"completionDateStruct":{"date":"2011-10","type":"ACTUAL"},"studyFirstSubmitDate":"2007-05-31","studyFirstSubmitQcDate":"2007-05-31","studyFirstPostDateStruct":{"date":"2007-06-04","type":"ESTIMATED"},"resultsFirstSubmitDate":"2012-10-26","resultsFirstSubmitQcDate":"2012-10-26","resultsFirstPostDateStruct":{"date":"2012-11-27","type":"ESTIMATED"},"lastUpdateSubmitDate":"2012-10-26","lastUpdatePostDateStruct":{"date":"2012-11-27","type":"ESTIMATED"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Eli Lilly and Company","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":true},"descriptionModule":{"briefSummary":"The primary purpose of this study is to determine the 2-year survival rate of both of the chemotherapy regimens in patients with inoperable non-small-cell lung cancer."},"conditionsModule":{"conditions":["Non-Small-Cell Lung Cancer"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE1","PHASE2"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":120,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"A: Pemetrexed + Carboplatin","type":"EXPERIMENTAL","description":"Pemetrexed + Carboplatin","interventionNames":["Drug: pemetrexed","Drug: carboplatin","Radiation: radiation therapy"]},{"label":"B: Pemetrexed + Cisplatin","type":"EXPERIMENTAL","description":"Pemetrexed + Cisplatin","interventionNames":["Drug: pemetrexed","Drug: cisplatin","Radiation: radiation therapy"]}],"interventions":[{"type":"DRUG","name":"pemetrexed","description":"Phase 1 - 500 milligram/meter squared (mg/m²), administered intravenously, every 21 days for 3 cycles\n\nPhase 2 - 500 mg/m², administered intravenously, every 21 days for 3 cycles\n\nConsolidation Therapy - 500 mg/m² pemetrexed, administered intravenously, every 21 days for 3 cycles beginning 3 weeks after completion of chemoradiation therapy for each phase","armGroupLabels":["A: Pemetrexed + Carboplatin","B: Pemetrexed + Cisplatin"],"otherNames":["LY231514","Alimta"]},{"type":"DRUG","name":"cisplatin","description":"Phase 1 - 30 mg/m² and 75 mg/m², administered intravenously, Days 1, 8, 22, 29 and 43\n\nPhase 2 - 75 mg/m², administered intravenously, every 21 days for 3 cycles","armGroupLabels":["B: Pemetrexed + Cisplatin"]},{"type":"DRUG","name":"carboplatin","description":"Phase 1 - dosed at area under the curve (AUC) 2 milligram/milliliter\\*minute (mg/mL\\*min), administered intravenously, Days 1, 8, 22, 29 and 43\n\nPhase 2 - dosed at AUC 5 mg/mL\\*min, administered intravenously, every 21 days for 3 cycles","armGroupLabels":["A: Pemetrexed + Carboplatin"]},{"type":"RADIATION","name":"radiation therapy","description":"Phase 1 - 2 Gray, daily, 5 days a week for Days 1-51\n\nPhase 2 - 2 Gray, daily, 5 days a week for Days 1-45","armGroupLabels":["A: Pemetrexed + Carboplatin","B: Pemetrexed + Cisplatin"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Phase 1 - Maximum Tolerated Dose (MTD) of Carboplatin","description":"MTD was defined as a dose at which the occurrence of at least 2 dose-limiting toxicities (DLTs) was observed. DLT was defined as any of the following events occurring during the entire radiation therapy (RT) course, including a 2-week recovery period following completion of RT: Grade 4 neutropenia (\\<0.5 x 10\\^9 cells per liter) lasting \\>7 days, febrile neutropenia; ≥Grade 3 neutropenia with fever \\>38.5 degrees Celsius (°C), Grade 4 thrombocytopenia, Grade 3 thrombocytopenia with ≥Grade 2 bleeding, ≥Grade 3 nonhematologic toxicity (excluding nausea, vomiting, and transaminase elevations) and ≥Grade 3 pulmonary or esophageal toxicity (radiation-related pneumonitis or esophagitis).","timeFrame":"Phase 1 enrollment to the end of study treatment up to Week 11"},{"measure":"Phase 1 - Maximum Tolerated Dose (MTD) of Cisplatin","description":"MTD was defined as a dose at which the occurrence of at least 2 dose-limiting toxicities (DLTs) was observed. DLT was defined as any of the following events occurring during the entire radiation therapy (RT) course, including a 2-week recovery period following completion of RT: Grade 4 neutropenia (\\<0.5 x 10\\^9 cells per liter) lasting \\>7 days, febrile neutropenia; ≥Grade 3 neutropenia with fever \\>38.5 degrees Celsius (°C), Grade 4 thrombocytopenia, Grade 3 thrombocytopenia with ≥Grade 2 bleeding, ≥Grade 3 nonhematologic toxicity (excluding nausea, vomiting, and transaminase elevations) and ≥Grade 3 pulmonary or esophageal toxicity (radiation-related pneumonitis or esophagitis).","timeFrame":"Phase 1 enrollment to the end of study treatment up to Week 11"},{"measure":"Phase 2 - Survival Probability at 2 Years","timeFrame":"Phase 2 randomization up to 2 years"}],"secondaryOutcomes":[{"measure":"Phase 1 - Pharmacology Toxicity: Number of Participants With Dose Limiting Toxicities (DLTs)","description":"Phase 1 pharmacology toxicity was defined as the number of participants experiencing dose limiting toxicities (DLTs). DLT was defined as any of the following events occurring during the entire radiation therapy (RT) course: Grade 4 neutropenia (\\<0.5 x 10\\^9 cells per liter) \\>7 days, febrile neutropenia, ≥Grade 3 neutropenia with fever \\>38.5 degrees Celsius (°C), Grade 4 thrombocytopenia, Grade 3 thrombocytopenia with ≥Grade 2 bleeding, ≥Grade 3 nonhematologic toxicity (excluding nausea, vomiting, and transaminase elevations), and ≥Grade 3 pulmonary or esophageal toxicity (radiation-related pneumonitis or esophagitis). Grade 5 events are the events leading to the death.","timeFrame":"Phase 1 enrollment up to Week 11"},{"measure":"Phase 1 - Percentage of Participants With Complete Response or Partial Response (Response Rate)","description":"Response rate is the percentage of participants with complete response (CR) or partial response (PR), as assessed according to the Response Evaluation Criteria In Solid Tumors (RECIST) guidelines. CR is disappearance of all target and non-target lesions; PR is ≥30% decrease in sum of longest diameter of target lesions. Response rate is calculated as a total number of participants with CR or PR divided by the total number of participants treated multiplied by 100.","timeFrame":"Phase 1 enrollment to the end of the study treatment up to Week 11"},{"measure":"Phase 2 - Pharmacology Toxicity: Number of Participants With Adverse Events","description":"Phase 2 pharmacology toxicity was defined as the number of participants who experienced serious adverse events or all other nonserious adverse events during the study. A summary of serious adverse events and other nonserious adverse events is located in the Reported Adverse Events section.","timeFrame":"Phase 2 randomization to the end of the study treatment up to 30.0 months"},{"measure":"Phase 2 - Time to Progression","description":"Time to disease progression was measured from randomization of Study Phase 2 to the first observation of disease progression according to the Response Evaluation Criteria In Solid Tumors (RECIST) criteria. Disease progression is ≥20% increase in sum of longest diameter of target lesions and/or a new lesion.","timeFrame":"Phase 2 randomization to measured disease progression up to 24 months"},{"measure":"Phase 2 - Median Survival","timeFrame":"Phase 2 randomization to death as the result of any cause up to 30.0 month"},{"measure":"Phase 2 - Percentage of Participants With Complete Response or Partial Response (Response Rate)","description":"Response rate is the percentage of participants with complete response (CR) or partial response (PR), as assessed according to the Response Evaluation Criteria In Solid Tumors (RECIST) guidelines. CR is disappearance of all target and non-target lesions; PR is ≥30% decrease in sum of longest diameter of target lesions. Response rate is calculated as a total number of participants with CR or PR divided by the total number of participants treated multiplied by 100.","timeFrame":"Phase 2 randomization to the end of the treatment up to 30.0 months"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Inoperable non small cell lung cancer\n* No weight loss greater than 10% in 3 months prior to enrolling in trial\n* Adequate kidney function\n* Adequate liver function\n* Adequate lung function\n\nExclusion Criteria:\n\n* Previous surgery to remove lung tumor\n* Previous chemotherapy or radiation therapy or lung cancer\n* Inability to take vitamin supplementation\n* Heart attack within past 6 months\n* Active infection","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)","affiliation":"Eli Lilly and Company","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Los Angeles","state":"California","zip":"90095","country":"United States","geoPoint":{"lat":34.05223,"lon":-118.24368}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Wichita","state":"Kansas","zip":"67214","country":"United States","geoPoint":{"lat":37.69224,"lon":-97.33754}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"St Louis","state":"Missouri","zip":"63110","country":"United States","geoPoint":{"lat":38.62727,"lon":-90.19789}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Las Vegas","state":"Nevada","zip":"89135","country":"United States","geoPoint":{"lat":36.17497,"lon":-115.13722}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Burlington","state":"North Carolina","zip":"27216","country":"United States","geoPoint":{"lat":36.09569,"lon":-79.4378}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Memphis","state":"Tennessee","zip":"38120","country":"United States","geoPoint":{"lat":35.14953,"lon":-90.04898}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Corpus Christi","state":"Texas","zip":"78405","country":"United States","geoPoint":{"lat":27.80058,"lon":-97.39638}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Dallas","state":"Texas","zip":"75390","country":"United States","geoPoint":{"lat":32.78306,"lon":-96.80667}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Temple","state":"Texas","zip":"76508","country":"United States","geoPoint":{"lat":31.09823,"lon":-97.34278}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Delhi","zip":"110085","country":"India","geoPoint":{"lat":28.65195,"lon":77.23149}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Trivandrum","zip":"695 011","country":"India","geoPoint":{"lat":8.4855,"lon":76.94924}}]},"referencesModule":{"seeAlsoLinks":[{"label":"Lilly Clinical Trial Registry","url":"http://www.lillytrials.com"}]}},"resultsSection":{"participantFlowModule":{"groups":[{"id":"FG000","title":"Pemetrexed + Carboplatin (Study Phase 1)","description":"500 milligrams/meter squared (mg/m²) pemetrexed (Pem) every 21 days for 3 cycles + Carboplatin (Carbo) dosed at area under the curve (AUC) 2 milligram/milliliter\\*minute (mg/mL\\*min) on Days 1, 8, 22, 29, 43 + radiation therapy (RT) 74 Grays (Gy) total dose given 2 Gy/day over 51 days.\n\nConsolidation Therapy - 500 mg/m² pemetrexed, administered intravenously, every 21 days for 3 cycles beginning 3 weeks after completion of chemoradiation (Pem + Carbo + RT) therapy."},{"id":"FG001","title":"Pemetrexed + Cisplatin (Study Phase 1)","description":"500 mg/m² pemetrexed every 21 days for 3 cycles + Cisplatin (Cis) 30 mg/m² or 75 mg/m² on Days 1, 8, 22, 29, 43 + radiation therapy 74 Gy total dose given 2 Gy/day over 51 days.\n\nConsolidation Therapy - 500 mg/m² pemetrexed, administered intravenously, every 21 days for 3 cycles beginning 3 weeks after completion of chemoradiation (Pem + Cis + RT) therapy."},{"id":"FG002","title":"Pemetrexed + Carboplatin (Study Phase 2)","description":"500 mg/m² pemetrexed every 21 days for 3 cycles + Carboplatin dosed at AUC 5 mg/mL\\*min every 21 days for 3 cycles + radiation therapy 64-68 Gy total dose given 2 Gy/day over 45 days.\n\nConsolidation Therapy - 500 mg/m² pemetrexed, administered intravenously, every 21 days for 3 cycles beginning 3 weeks after completion of chemoradiation (Pem + Carbo + RT) therapy."},{"id":"FG003","title":"Pemetrexed + Cisplatin (Study Phase 2)","description":"500 mg/m² pemetrexed every 21 days for 3 cycles + Cisplatin 75 mg/m² every 21 days for 3 cycles + radiation therapy 64-68 Gy total dose given 2 Gy/day over 45 days.\n\nConsolidation Therapy - 500 mg/m² pemetrexed, administered intravenously, every 21 days for 3 cycles beginning 3 weeks after completion of chemoradiation (Pem + Cis + RT) therapy."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"9"},{"groupId":"FG001","numSubjects":"13"},{"groupId":"FG002","numSubjects":"46"},{"groupId":"FG003","numSubjects":"52"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"7"},{"groupId":"FG002","numSubjects":"35"},{"groupId":"FG003","numSubjects":"29"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"7"},{"groupId":"FG001","numSubjects":"6"},{"groupId":"FG002","numSubjects":"11"},{"groupId":"FG003","numSubjects":"23"}]}],"dropWithdraws":[{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"2"},{"groupId":"FG002","numSubjects":"3"},{"groupId":"FG003","numSubjects":"4"}]},{"type":"Adverse Event","reasons":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"2"},{"groupId":"FG003","numSubjects":"8"}]},{"type":"Death","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"2"},{"groupId":"FG002","numSubjects":"1"},{"groupId":"FG003","numSubjects":"4"}]},{"type":"Lack of Efficacy","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"4"},{"groupId":"FG003","numSubjects":"6"}]},{"type":"Sponsor Decision","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"2"},{"groupId":"FG002","numSubjects":"1"},{"groupId":"FG003","numSubjects":"1"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"Pemetrexed + Carboplatin (Study Phase 1)","description":"500 milligrams/meter squared (mg/m²) pemetrexed (Pem) every 21 days for 3 cycles + Carboplatin (Carbo) dosed at area under the curve (AUC) 2 milligram/milliliter\\*minute (mg/mL\\*min) on Days 1, 8, 22, 29, 43 + radiation therapy (RT) 74 Grays (Gy) total dose given 2 Gy/day over 51 days.\n\nConsolidation Therapy - 500 mg/m² pemetrexed, administered intravenously, every 21 days for 3 cycles beginning 3 weeks after completion of chemoradiation (Pem + Carbo + RT) therapy."},{"id":"BG001","title":"Pemetrexed + Cisplatin (Study Phase 1)","description":"500 mg/m² pemetrexed every 21 days for 3 cycles + Cisplatin (Cis) 30 mg/m² or 75 mg/m² on Days 1, 8, 22, 29, 43 + radiation therapy 74 Gy total dose given 2 Gy/day over 51 days.\n\nConsolidation Therapy - 500 mg/m² pemetrexed, administered intravenously, every 21 days for 3 cycles beginning 3 weeks after completion of chemoradiation (Pem + Cis + RT) therapy."},{"id":"BG002","title":"Pemetrexed + Carboplatin (Study Phase 2)","description":"500 mg/m² pemetrexed every 21 days for 3 cycles + Carboplatin dosed at AUC 5 mg/mL\\*min every 21 days for 3 cycles + radiation therapy 64-68 Gy total dose given 2 Gy/day over 45 days.\n\nConsolidation Therapy - 500 mg/m² pemetrexed, administered intravenously, every 21 days for 3 cycles beginning 3 weeks after completion of chemoradiation (Pem + Carbo + RT) therapy."},{"id":"BG003","title":"Pemetrexed + Cisplatin (Study Phase 2)","description":"500 mg/m² pemetrexed every 21 days for 3 cycles + Cisplatin 75 mg/m² every 21 days for 3 cycles + radiation therapy 64-68 Gy total dose given 2 Gy/day over 45 days.\n\nConsolidation Therapy - 500 mg/m² pemetrexed, administered intravenously, every 21 days for 3 cycles beginning 3 weeks after completion of chemoradiation (Pem + Cis + RT) therapy."},{"id":"BG004","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"9"},{"groupId":"BG001","value":"13"},{"groupId":"BG002","value":"46"},{"groupId":"BG003","value":"52"},{"groupId":"BG004","value":"120"}]}],"measures":[{"title":"Age Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"Years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"61.9","spread":"8.70"},{"groupId":"BG001","value":"61.0","spread":"11.66"},{"groupId":"BG002","value":"63.6","spread":"9.92"},{"groupId":"BG003","value":"64.1","spread":"9.44"},{"groupId":"BG004","value":"63.4","spread":"9.77"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"16"},{"groupId":"BG003","value":"21"},{"groupId":"BG004","value":"43"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"7"},{"groupId":"BG001","value":"9"},{"groupId":"BG002","value":"30"},{"groupId":"BG003","value":"31"},{"groupId":"BG004","value":"77"}]}]}]},{"title":"Race/Ethnicity, Customized","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"Caucasian","categories":[{"measurements":[{"groupId":"BG000","value":"8","spread":"73.3"},{"groupId":"BG001","value":"7"},{"groupId":"BG002","value":"36"},{"groupId":"BG003","value":"37"},{"groupId":"BG004","value":"88"}]}]},{"title":"African","categories":[{"measurements":[{"groupId":"BG000","value":"1","spread":"11.7"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"5"},{"groupId":"BG003","value":"5"},{"groupId":"BG004","value":"14"}]}]},{"title":"Hispanic","categories":[{"measurements":[{"groupId":"BG000","value":"0","spread":"1.7"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"2"}]}]},{"title":"East Asian","categories":[{"measurements":[{"groupId":"BG000","value":"0","spread":"1.7"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"1"},{"groupId":"BG004","value":"2"}]}]},{"title":"West Asian (Indian sub continent","categories":[{"measurements":[{"groupId":"BG000","value":"0","spread":"11.7"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"3"},{"groupId":"BG003","value":"9"},{"groupId":"BG004","value":"14"}]}]}]},{"title":"Region of Enrollment","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"United States","categories":[{"measurements":[{"groupId":"BG000","value":"9"},{"groupId":"BG001","value":"13"},{"groupId":"BG002","value":"43"},{"groupId":"BG003","value":"43"},{"groupId":"BG004","value":"108"}]}]},{"title":"India","categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"3"},{"groupId":"BG003","value":"9"},{"groupId":"BG004","value":"12"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Phase 1 - Maximum Tolerated Dose (MTD) of Carboplatin","description":"MTD was defined as a dose at which the occurrence of at least 2 dose-limiting toxicities (DLTs) was observed. DLT was defined as any of the following events occurring during the entire radiation therapy (RT) course, including a 2-week recovery period following completion of RT: Grade 4 neutropenia (\\<0.5 x 10\\^9 cells per liter) lasting \\>7 days, febrile neutropenia; ≥Grade 3 neutropenia with fever \\>38.5 degrees Celsius (°C), Grade 4 thrombocytopenia, Grade 3 thrombocytopenia with ≥Grade 2 bleeding, ≥Grade 3 nonhematologic toxicity (excluding nausea, vomiting, and transaminase elevations) and ≥Grade 3 pulmonary or esophageal toxicity (radiation-related pneumonitis or esophagitis).","populationDescription":"All participants who were enrolled in Study Phase 1 and completed at least 6 weeks of pemetrexed + carboplatin treatment.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"milligram/milliliter*minute (mg/mL*min)","timeFrame":"Phase 1 enrollment to the end of study treatment up to Week 11","groups":[{"id":"OG000","title":"Pemetrexed + Carboplatin Treatment Group","description":"500 milligrams/meter squared (mg/m²) pemetrexed (Pem) every 21 days for 3 cycles + Carboplatin (Carbo) dosed at area under the curve (AUC) 2 milligram/milliliter\\*minute (mg/mL\\*min) on Days 1, 8, 22, 29, 43 + radiation therapy (RT) 74 Grays (Gy) total dose given 2 Gy/day over 51 days.\n\nConsolidation Therapy - 500 mg/m² pemetrexed, administered intravenously, every 21 days for 3 cycles beginning 3 weeks after completion of chemoradiation (Pem + Carbo + RT) therapy."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","comment":"MTD was not reached because 2 DLTs threshold wasn't reached."}]}]}]},{"type":"PRIMARY","title":"Phase 1 - Maximum Tolerated Dose (MTD) of Cisplatin","description":"MTD was defined as a dose at which the occurrence of at least 2 dose-limiting toxicities (DLTs) was observed. DLT was defined as any of the following events occurring during the entire radiation therapy (RT) course, including a 2-week recovery period following completion of RT: Grade 4 neutropenia (\\<0.5 x 10\\^9 cells per liter) lasting \\>7 days, febrile neutropenia; ≥Grade 3 neutropenia with fever \\>38.5 degrees Celsius (°C), Grade 4 thrombocytopenia, Grade 3 thrombocytopenia with ≥Grade 2 bleeding, ≥Grade 3 nonhematologic toxicity (excluding nausea, vomiting, and transaminase elevations) and ≥Grade 3 pulmonary or esophageal toxicity (radiation-related pneumonitis or esophagitis).","populationDescription":"All participants who were enrolled in Study Phase 1 and completed at least 6 weeks of pemetrexed + cisplatin treatment.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"milligrams/meter squared (mg/m²)","timeFrame":"Phase 1 enrollment to the end of study treatment up to Week 11","groups":[{"id":"OG000","title":"Pemetrexed + Cisplatin Treatment Group","description":"500 milligrams/meter squared (mg/m²) pemetrexed every 21 days for 3 cycles + Cisplatin (Cis) 30 mg/m² or 75 mg/m² on Days 1, 8, 22, 29, 43 + radiation therapy 74 Gy total dose given 2 Gy/day over 51 days.\n\nConsolidation Therapy - 500 mg/m² pemetrexed, administered intravenously, every 21 days for 3 cycles beginning 3 weeks after completion of chemoradiation (Pem + Cis + RT) therapy."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","comment":"MTD was not reached because 2 DLTs threshold wasn't reached."}]}]}]},{"type":"SECONDARY","title":"Phase 1 - Pharmacology Toxicity: Number of Participants With Dose Limiting Toxicities (DLTs)","description":"Phase 1 pharmacology toxicity was defined as the number of participants experiencing dose limiting toxicities (DLTs). DLT was defined as any of the following events occurring during the entire radiation therapy (RT) course: Grade 4 neutropenia (\\<0.5 x 10\\^9 cells per liter) \\>7 days, febrile neutropenia, ≥Grade 3 neutropenia with fever \\>38.5 degrees Celsius (°C), Grade 4 thrombocytopenia, Grade 3 thrombocytopenia with ≥Grade 2 bleeding, ≥Grade 3 nonhematologic toxicity (excluding nausea, vomiting, and transaminase elevations), and ≥Grade 3 pulmonary or esophageal toxicity (radiation-related pneumonitis or esophagitis). Grade 5 events are the events leading to the death.","populationDescription":"All participants who were enrolled in Study Phase 1 and received at least 1 dose of study drug and 1 dose of radiation therapy.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"participants","timeFrame":"Phase 1 enrollment up to Week 11","groups":[{"id":"OG000","title":"Pemetrexed + Carboplatin Treatment Group","description":"500 milligrams/meter squared (mg/m²) pemetrexed (Pem) every 21 days for 3 cycles + Carboplatin (Carbo) dosed at area under the curve (AUC) 2 milligram/milliliter\\*minute (mg/mL\\*min) on Days 1, 8, 22, 29, 43 + radiation therapy (RT) 74 Grays (Gy) total dose given 2 Gy/day over 51 days.\n\nConsolidation Therapy - 500 mg/m² pemetrexed, administered intravenously, every 21 days for 3 cycles beginning 3 weeks after completion of chemoradiation (Pem + Carbo + RT) therapy."},{"id":"OG001","title":"Pemetrexed + Cisplatin Treatment","description":"500 mg/m² pemetrexed every 21 days for 3 cycles + Cisplatin (Cis) 30 mg/m² or 75 mg/m² on Days 1, 8, 22, 29, 43 + radiation therapy 74 Gy total dose given 2 Gy/day over 51 days.\n\nConsolidation Therapy - 500 mg/m² pemetrexed, administered intravenously, every 21 days for 3 cycles beginning 3 weeks after completion of chemoradiation (Pem + Cis + RT) therapy."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"11"}]}],"classes":[{"title":"Grade 5 Pneumocystis jiroveci pneumonia","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}]}]},{"title":"Grade 5 Hemoptysis (pemetrexed+Cisplatin30 mg/m² )","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}]}]},{"type":"SECONDARY","title":"Phase 1 - Percentage of Participants With Complete Response or Partial Response (Response Rate)","description":"Response rate is the percentage of participants with complete response (CR) or partial response (PR), as assessed according to the Response Evaluation Criteria In Solid Tumors (RECIST) guidelines. CR is disappearance of all target and non-target lesions; PR is ≥30% decrease in sum of longest diameter of target lesions. Response rate is calculated as a total number of participants with CR or PR divided by the total number of participants treated multiplied by 100.","populationDescription":"All participants who were enrolled in Study Phase 1 and received at least 1 dose of study drug and 1 dose of radiation therapy.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"Phase 1 enrollment to the end of the study treatment up to Week 11","groups":[{"id":"OG000","title":"Pemetrexed + Carboplatin Treatment Group","description":"500 milligrams/meter squared (mg/m²) pemetrexed (Pem) every 21 days for 3 cycles + Carboplatin (Carbo) dosed at area under the curve (AUC) 2 milligram/milliliter\\*minute (mg/mL\\*min) on Days 1, 8, 22, 29, 43 + radiation therapy (RT) 74 Grays (Gy) total dose given 2 Gy/day over 51 days.\n\nConsolidation Therapy - 500 mg/m² pemetrexed, administered intravenously, every 21 days for 3 cycles beginning 3 weeks after completion of chemoradiation (Pem + Carbo + RT) therapy."},{"id":"OG001","title":"Pemetrexed + Cisplatin Treatment","description":"500 mg/m² pemetrexed every 21 days for 3 cycles + Cisplatin (Cis) 30 mg/m² or 75 mg/m² on Days 1, 8, 22, 29, 43 + radiation therapy 74 Gy total dose given 2 Gy/day over 51 days.\n\nConsolidation Therapy - 500 mg/m² pemetrexed, administered intravenously, every 21 days for 3 cycles beginning 3 weeks after completion of chemoradiation (Pem + Cis + RT) therapy."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"11"}]}],"classes":[{"title":"Complete Response (CR)","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.0"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"0.0"}]}]},{"title":"Partial Response (PR)","categories":[{"measurements":[{"groupId":"OG000","value":"11.1","lowerLimit":"0.28","upperLimit":"48.25"},{"groupId":"OG001","value":"45.5","lowerLimit":"16.75","upperLimit":"76.62"}]}]}]},{"type":"SECONDARY","title":"Phase 2 - Pharmacology Toxicity: Number of Participants With Adverse Events","description":"Phase 2 pharmacology toxicity was defined as the number of participants who experienced serious adverse events or all other nonserious adverse events during the study. A summary of serious adverse events and other nonserious adverse events is located in the Reported Adverse Events section.","populationDescription":"All randomized participants who received at least 1 dose of study drug or 1 dose of radiation therapy (RT) during Study Phase 2.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"participants","timeFrame":"Phase 2 randomization to the end of the study treatment up to 30.0 months","groups":[{"id":"OG000","title":"Pemetrexed + Carboplatin Treatment Group","description":"500 milligrams/meter squared (mg/m²) pemetrexed (Pem) every 21 days for 3 cycles + Carboplatin (Carbo) dosed at area under the curve (AUC) 5 milligram/milliliter\\*minute (mg/mL\\*min) every 21 days for 3 cycles + radiation therapy (RT) 64-68 (Gray) Gy total dose given 2 Gy/day over 45 days.\n\nConsolidation Therapy - 500 mg/m² pemetrexed, administered intravenously, every 21 days for 3 cycles beginning 3 weeks after completion of chemoradiation (Pem + Carbo + RT) therapy."},{"id":"OG001","title":"Pemetrexed + Cisplatin Treatment Group","description":"500 mg/m² pemetrexed every 21 days for 3 cycles + Cisplatin (Cis) 75 mg/m² every 21 days for 3 cycles + radiation therapy 64-68 Gy total dose given 2 Gy/day over 45 days.\n\nConsolidation Therapy - 500 mg/m² pemetrexed, administered intravenously, every 21 days for 3 cycles beginning 3 weeks after completion of chemoradiation (Pem + Cis + RT) therapy."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"46"},{"groupId":"OG001","value":"52"}]}],"classes":[{"title":"Serious Adverse Events","categories":[{"measurements":[{"groupId":"OG000","value":"21","lowerLimit":"6.0","upperLimit":"12.6"},{"groupId":"OG001","value":"19","lowerLimit":"8.3","upperLimit":"NA"}]}]},{"title":"Other Nonserious Adverse Events","categories":[{"measurements":[{"groupId":"OG000","value":"44"},{"groupId":"OG001","value":"51"}]}]}]},{"type":"SECONDARY","title":"Phase 2 - Time to Progression","description":"Time to disease progression was measured from randomization of Study Phase 2 to the first observation of disease progression according to the Response Evaluation Criteria In Solid Tumors (RECIST) criteria. Disease progression is ≥20% increase in sum of longest diameter of target lesions and/or a new lesion.","populationDescription":"All randomized participants in Study Phase 2.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"Phase 2 randomization to measured disease progression up to 24 months","groups":[{"id":"OG000","title":"Pemetrexed + Carboplatin Treatment Group","description":"500 milligrams/meter squared (mg/m²) pemetrexed (Pem) every 21 days for 3 cycles + Carboplatin (Carbo) dosed at area under the curve (AUC) 5 milligram/milliliter\\*minute (mg/mL\\*min) every 21 days for 3 cycles + radiation therapy (RT) 64-68 (Gray) Gy total dose given 2 Gy/day over 45 days.\n\nConsolidation Therapy - 500 mg/m² pemetrexed, administered intravenously, every 21 days for 3 cycles beginning 3 weeks after completion of chemoradiation (Pem + Carbo + RT) therapy."},{"id":"OG001","title":"Pemetrexed + Cisplatin Treatment Group","description":"500 mg/m² pemetrexed every 21 days for 3 cycles + Cisplatin (Cis) 75 mg/m² every 21 days for 3 cycles + radiation therapy 64-68 Gy total dose given 2 Gy/day over 45 days.\n\nConsolidation Therapy - 500 mg/m² pemetrexed, administered intravenously, every 21 days for 3 cycles beginning 3 weeks after completion of chemoradiation (Pem + Cis + RT) therapy."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"46"},{"groupId":"OG001","value":"52"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.8","lowerLimit":"6.0","upperLimit":"12.6"},{"groupId":"OG001","value":"13.1","lowerLimit":"8.3","upperLimit":"NA","comment":"The upper limit of the 95% confidence interval was not calculable because an insufficient number of participants reached the event at the final time point for assessment."}]}]}]},{"type":"SECONDARY","title":"Phase 2 - Median Survival","populationDescription":"All randomized participants in Study Phase 2.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"Phase 2 randomization to death as the result of any cause up to 30.0 month","groups":[{"id":"OG000","title":"Pemetrexed + Carboplatin Treatment Group","description":"500 milligrams/meter squared (mg/m²) pemetrexed (Pem) every 21 days for 3 cycles + Carboplatin (Carbo) dosed at area under the curve (AUC) 5 milligram/milliliter\\*minute (mg/mL\\*min) every 21 days for 3 cycles + radiation therapy (RT) 64-68 Gray (Gy) total dose given 2 Gy/day over 45 days.\n\nConsolidation Therapy - 500 mg/m² pemetrexed, administered intravenously, every 21 days for 3 cycles beginning 3 weeks after completion of chemoradiation (Pem + Carbo + RT) therapy."},{"id":"OG001","title":"Pemetrexed + Cisplatin Treatment Group","description":"500 mg/m² pemetrexed every 21 days for 3 cycles + Cisplatin (Cis) 75 mg/m² every 21 days for 3 cycles + radiation therapy 64-68 Gy total dose given 2 Gy/day over 45 days.\n\nConsolidation Therapy - 500 mg/m² pemetrexed, administered intravenously, every 21 days for 3 cycles beginning 3 weeks after completion of chemoradiation (Pem + Cis + RT) therapy."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"46"},{"groupId":"OG001","value":"52"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"18.7","lowerLimit":"12.9","upperLimit":"NA","comment":"The upper limit of the 95% confidence interval was not calculable because an insufficient number of participants reached the event at the final time point for assessment."},{"groupId":"OG001","value":"27.0","lowerLimit":"23.2","upperLimit":"NA","comment":"The upper limit of the 95% confidence interval was not calculable because an insufficient number of participants reached the event at the final time point for assessment."}]}]}]},{"type":"SECONDARY","title":"Phase 2 - Percentage of Participants With Complete Response or Partial Response (Response Rate)","description":"Response rate is the percentage of participants with complete response (CR) or partial response (PR), as assessed according to the Response Evaluation Criteria In Solid Tumors (RECIST) guidelines. CR is disappearance of all target and non-target lesions; PR is ≥30% decrease in sum of longest diameter of target lesions. Response rate is calculated as a total number of participants with CR or PR divided by the total number of participants treated multiplied by 100.","populationDescription":"All randomization participants in Study Phase 2.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"Phase 2 randomization to the end of the treatment up to 30.0 months","groups":[{"id":"OG000","title":"Pemetrexed + Carboplatin Treatment Group","description":"500 milligrams/meter squared (mg/m²) pemetrexed (Pem) every 21 days for 3 cycles + Carboplatin (Carbo) dosed at area under the curve (AUC) 5 milligram/milliliter\\*minute (mg/mL\\*min) every 21 days for 3 cycles + radiation therapy (RT) 64-68 (Gray) Gy total dose given 2 Gy/day over 45 days.\n\nConsolidation Therapy - 500 mg/m² pemetrexed, administered intravenously, every 21 days for 3 cycles beginning 3 weeks after completion of chemoradiation (Pem + Carbo + RT) therapy."},{"id":"OG001","title":"Pemetrexed + Cisplatin Treatment Group","description":"500 mg/m² pemetrexed every 21 days for 3 cycles + Cisplatin (Cis) 75 mg/m² every 21 days for 3 cycles + radiation therapy 64-68 Gy total dose given 2 Gy/day over 45 days.\n\nConsolidation Therapy - 500 mg/m² pemetrexed, administered intravenously, every 21 days for 3 cycles beginning 3 weeks after completion of chemoradiation (Pem + Cis + RT) therapy."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"46"},{"groupId":"OG001","value":"52"}]}],"classes":[{"title":"Complete Response (CR)","categories":[{"measurements":[{"groupId":"OG000","value":"6.5","lowerLimit":"1.4","upperLimit":"17.9"},{"groupId":"OG001","value":"3.8","lowerLimit":"0.5","upperLimit":"13.2"}]}]},{"title":"Partial Response (PR)","categories":[{"measurements":[{"groupId":"OG000","value":"45.7","lowerLimit":"30.9","upperLimit":"61.0"},{"groupId":"OG001","value":"42.3","lowerLimit":"28.7","upperLimit":"56.8"}]}]}]},{"type":"PRIMARY","title":"Phase 2 - Survival Probability at 2 Years","populationDescription":"All randomized participants in Study Phase 2.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage survival","timeFrame":"Phase 2 randomization up to 2 years","groups":[{"id":"OG000","title":"Pemetrexed + Carboplatin Treatment Group","description":"500 milligrams/meter squared (mg/m²) pemetrexed (Pem) every 21 days for 3 cycles + Carboplatin (Carbo) dosed at area under the curve (AUC) 5 milligram/milliliter\\*minute (mg/mL\\*min) every 21 days for 3 cycles + radiation therapy (RT) 64-68 Gray (Gy) total dose given 2 Gy/day over 45 days.\n\nConsolidation Therapy - 500 mg/m² pemetrexed, administered intravenously, every 21 days for 3 cycles beginning 3 weeks after completion of chemoradiation (Pem + Carbo + RT) therapy."},{"id":"OG001","title":"Pemetrexed + Cisplatin Treatment Group","description":"500 mg/m² pemetrexed every 21 days for 3 cycles + Cisplatin (Cis) 75 mg/m² every 21 days for 3 cycles + radiation therapy 64-68 Gy total dose given 2 Gy/day over 45 days.\n\nConsolidation Therapy - 500 mg/m² pemetrexed, administered intravenously, every 21 days for 3 cycles beginning 3 weeks after completion of chemoradiation (Pem + Cis + RT) therapy."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"46"},{"groupId":"OG001","value":"52"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"45.4","lowerLimit":"29.5","upperLimit":"60.0"},{"groupId":"OG001","value":"58.4","lowerLimit":"42.6","upperLimit":"71.3"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"5","eventGroups":[{"id":"EG000","title":"Phase 1: Pemetrexed + Carboplatin","description":"500 milligrams/meter squared (mg/m²) pemetrexed (pem) every 21 days for 3 cycles + Carboplatin (Carbo) dosed at area under the curve (AUC) 2 milligram/milliliter\\*minute (mg/mL\\*min) on Days 1, 8, 22, 29, 43 + radiation therapy (RT) 74 Grays (Gy) total dose given 2 Gy/day over 51 days.\n\nConsolidation Therapy - 500 mg/m² pemetrexed, administered intravenously, every 21 days for 3 cycles beginning 3 weeks after completion of chemoradiation (Pem + Carbo + RT) therapy.","seriousNumAffected":6,"seriousNumAtRisk":9,"otherNumAffected":9,"otherNumAtRisk":9},{"id":"EG001","title":"Phase 1: Pemetrexed + Cisplatin","description":"500 mg/m² pemetrexed every 21 days for 3 cycles + Cisplatin (Cis) 30 mg/m² or 75 mg/m² on Days 1, 8, 22, 29, 43 + radiation therapy 74 Grays (Gy) total dose given 2 Gy/day over 51 days.\n\nConsolidation Therapy - 500 mg/m² pemetrexed, administered intravenously, every 21 days for 3 cycles beginning 3 weeks after completion of chemoradiation (Pem + Cis + RT) therapy.","seriousNumAffected":5,"seriousNumAtRisk":13,"otherNumAffected":10,"otherNumAtRisk":13},{"id":"EG002","title":"Phase 2: Pemetrexed + Carboplatin","description":"500 mg/m² pemetrexed every 21 days for 3 cycles + Carboplatin dosed at AUC 5 mg/mL\\*min every 21 days for 3 cycles + radiation therapy 64-68 Gy total dose given 2 Gy/day over 45 days.\n\nConsolidation Therapy - 500 mg/m² pemetrexed, administered intravenously, every 21 days for 3 cycles beginning 3 weeks after completion of chemoradiation (Pem + Carbo + RT) therapy.","seriousNumAffected":21,"seriousNumAtRisk":46,"otherNumAffected":44,"otherNumAtRisk":46},{"id":"EG003","title":"Phase 2: Pemetrexed + Cisplatin","description":"500 mg/m² pemetrexed every 21 days for 3 cycles + Cisplatin 75 mg/m² every 21 days for 3 cycles + radiation therapy 64-68 Gy total dose given 2 Gy/day over 45 days.\n\nConsolidation Therapy - 500 mg/m² pemetrexed, administered intravenously, every 21 days for 3 cycles beginning 3 weeks after completion of chemoradiation (Pem + Cis + RT) therapy.","seriousNumAffected":19,"seriousNumAtRisk":52,"otherNumAffected":51,"otherNumAtRisk":52}],"seriousEvents":[{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 11","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":46},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":52}]},{"term":"Febrile neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 11","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":46},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":52}]},{"term":"Neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 11","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":9},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":46},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":52}]},{"term":"Thrombocytopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 11","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":46},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":52}]},{"term":"Angina pectoris","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 11","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":46},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":52}]},{"term":"Atrial fibrillation","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 11","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":46},{"groupId":"EG003","numEvents":3,"numAffected":3,"numAtRisk":52}]},{"term":"Cardiac failure congestive","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 11","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":46},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":52}]},{"term":"Cardio-respiratory arrest","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 11","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":46},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":52}]},{"term":"Cardiopulmonary failure","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 11","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":46},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":52}]},{"term":"Myocardial infarction","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 11","assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"One of the events resulted in a discontinuation due to death.","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":46},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":52}]},{"term":"Oedema peripheral","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 11","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":46},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":52}]},{"term":"Palpitations","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 11","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":46},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":52}]},{"term":"Supraventricular tachycardia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 11","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":46},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":52}]},{"term":"Tracheo-oesophageal fistula","organSystem":"Congenital, familial and genetic disorders","sourceVocabulary":"MedDRA 11","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":46},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":52}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 11","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":46},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":52}]},{"term":"Dysphagia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 11","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13},{"groupId":"EG002","numEvents":3,"numAffected":3,"numAtRisk":46},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":52}]},{"term":"Gastritis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 11","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":46},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":52}]},{"term":"Haematemesis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 11","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":46},{"groupId":"EG003","numEvents":2,"numAffected":1,"numAtRisk":52}]},{"term":"Hiatus hernia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 11","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":46},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":52}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 11","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG002","numEvents":4,"numAffected":4,"numAtRisk":46},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":52}]},{"term":"Oesophagitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 11","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG002","numEvents":3,"numAffected":3,"numAtRisk":46},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":52}]},{"term":"Rectal haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 11","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":46},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":52}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 11","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG002","numEvents":4,"numAffected":4,"numAtRisk":46},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":52}]},{"term":"Asthenia","organSystem":"General disorders","sourceVocabulary":"MedDRA 11","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":46},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":52}]},{"term":"Chest pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 11","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":46},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":52}]},{"term":"Death","organSystem":"General disorders","sourceVocabulary":"MedDRA 11","assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"The event in Pemetrexed + Cisplatin resulted in a discontinuation due to death.","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":46},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":52}]},{"term":"General physical health deterioration","organSystem":"General disorders","sourceVocabulary":"MedDRA 11","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":46},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":52}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA 11","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":13},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":46},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":52}]},{"term":"Cellulitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 11","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":46},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":52}]},{"term":"Dysentery","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 11","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":46},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":52}]},{"term":"Herpes oesophagitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 11","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":46},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":52}]},{"term":"Localised infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 11","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":46},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":52}]},{"term":"Lung infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 11","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":46},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":52}]},{"term":"Mediastinitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 11","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG002","numEvents":2,"numAffected":1,"numAtRisk":46},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":52}]},{"term":"Oesophageal candidiasis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 11","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":46},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":52}]},{"term":"Pneumocystis jiroveci pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 11","assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"This event resulted in a discontinuation due to death.","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":46},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":52}]},{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 11","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":9},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":46},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":52}]},{"term":"Pseudomembranous colitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 11","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":46},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":52}]},{"term":"Urinary tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 11","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":46},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":52}]},{"term":"Radiation oesophagitis","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 11","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":46},{"groupId":"EG003","numEvents":3,"numAffected":2,"numAtRisk":52}]},{"term":"Radiation pneumonitis","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 11","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":46},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":52}]},{"term":"Radiation skin injury","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 11","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":46},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":52}]},{"term":"Subdural haematoma","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 11","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":13},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":46},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":52}]},{"term":"Dehydration","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 11","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG002","numEvents":5,"numAffected":5,"numAtRisk":46},{"groupId":"EG003","numEvents":8,"numAffected":5,"numAtRisk":52}]},{"term":"Failure to thrive","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 11","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":46},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":52}]},{"term":"Hyperkalaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 11","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":46},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":52}]},{"term":"Hypovolaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 11","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":46},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":52}]},{"term":"Muscular weakness","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 11","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":46},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":52}]},{"term":"Neoplasm malignant","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 11","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":46},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":52}]},{"term":"Cerebral infarction","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 11","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":46},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":52}]},{"term":"Convulsion","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 11","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":46},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":52}]},{"term":"Dizziness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 11","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG002","numEvents":2,"numAffected":1,"numAtRisk":46},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":52}]},{"term":"Neuropathy peripheral","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 11","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":46},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":52}]},{"term":"Spinal cord compression","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 11","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":46},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":52}]},{"term":"Syncope","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 11","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":46},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":52}]},{"term":"Confusional state","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 11","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":46},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":52}]},{"term":"Acute respiratory distress syndrome","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 11","assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"This event resulted in a discontinuation due to death.","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":46},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":52}]},{"term":"Bronchopleural fistula","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 11","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":46},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":52}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 11","assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"The event in Pemetrexed + Cisplatin treatment group resulted in a discontinuation due to death.","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":46},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":52}]},{"term":"Haemoptysis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 11","assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"This event resulted in a discontinuation due to death.","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":46},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":52}]},{"term":"Pneumonitis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 11","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":46},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":52}]},{"term":"Pneumothorax","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 11","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":46},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":52}]},{"term":"Respiratory failure","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 11","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":46},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":52}]},{"term":"Thoracotomy","organSystem":"Surgical and medical procedures","sourceVocabulary":"MedDRA 11","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":46},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":52}]},{"term":"Deep vein thrombosis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 11","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":46},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":52}]},{"term":"Hypertension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 11","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":46},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":52}]},{"term":"Hypotension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 11","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":46},{"groupId":"EG003","numEvents":7,"numAffected":5,"numAtRisk":52}]},{"term":"Orthostatic hypotension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 11","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":46},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":52}]},{"term":"Pulmonary embolism","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 11","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":46},{"groupId":"EG003","numEvents":4,"numAffected":4,"numAtRisk":52}]}],"otherEvents":[{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 11","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":9},{"groupId":"EG001","numEvents":6,"numAffected":5,"numAtRisk":13},{"groupId":"EG002","numEvents":24,"numAffected":14,"numAtRisk":46},{"groupId":"EG003","numEvents":23,"numAffected":16,"numAtRisk":52}]},{"term":"Leukopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 11","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":9},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13},{"groupId":"EG002","numEvents":6,"numAffected":5,"numAtRisk":46},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":52}]},{"term":"Lymphopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 11","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG002","numEvents":5,"numAffected":4,"numAtRisk":46},{"groupId":"EG003","numEvents":3,"numAffected":3,"numAtRisk":52}]},{"term":"Neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 11","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":9},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13},{"groupId":"EG002","numEvents":27,"numAffected":16,"numAtRisk":46},{"groupId":"EG003","numEvents":15,"numAffected":12,"numAtRisk":52}]},{"term":"Pancytopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 11","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":46},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":52}]},{"term":"Thrombocythaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 11","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":46},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":52}]},{"term":"Thrombocytopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 11","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":9},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":13},{"groupId":"EG002","numEvents":8,"numAffected":4,"numAtRisk":46},{"groupId":"EG003","numEvents":7,"numAffected":5,"numAtRisk":52}]},{"term":"Atrial fibrillation","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 11","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":46},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":52}]},{"term":"Cardiac failure congestive","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 11","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":46},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":52}]},{"term":"Oedema peripheral","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 11","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":13},{"groupId":"EG002","numEvents":6,"numAffected":4,"numAtRisk":46},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":52}]},{"term":"Tachycardia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 11","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG002","numEvents":3,"numAffected":3,"numAtRisk":46},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":52}]},{"term":"Tinnitus","organSystem":"Ear and labyrinth disorders","sourceVocabulary":"MedDRA 11","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":46},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":52}]},{"term":"Vision blurred","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 11","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13},{"groupId":"EG002","numEvents":3,"numAffected":3,"numAtRisk":46},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":52}]},{"term":"Abdominal distension","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 11","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":46},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":52}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 11","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":9},{"groupId":"EG001","numEvents":6,"numAffected":4,"numAtRisk":13},{"groupId":"EG002","numEvents":17,"numAffected":14,"numAtRisk":46},{"groupId":"EG003","numEvents":16,"numAffected":15,"numAtRisk":52}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 11","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":9},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":13},{"groupId":"EG002","numEvents":7,"numAffected":5,"numAtRisk":46},{"groupId":"EG003","numEvents":10,"numAffected":10,"numAtRisk":52}]},{"term":"Dry mouth","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 11","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":46},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":52}]},{"term":"Dyspepsia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 11","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":9},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13},{"groupId":"EG002","numEvents":8,"numAffected":7,"numAtRisk":46},{"groupId":"EG003","numEvents":8,"numAffected":7,"numAtRisk":52}]},{"term":"Dysphagia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 11","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":8,"numAffected":6,"numAtRisk":9},{"groupId":"EG001","numEvents":5,"numAffected":5,"numAtRisk":13},{"groupId":"EG002","numEvents":20,"numAffected":19,"numAtRisk":46},{"groupId":"EG003","numEvents":25,"numAffected":18,"numAtRisk":52}]},{"term":"Gastrooesophageal reflux disease","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 11","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG002","numEvents":3,"numAffected":3,"numAtRisk":46},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":52}]},{"term":"Hiatus hernia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 11","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":46},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":52}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 11","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":4,"numAtRisk":9},{"groupId":"EG001","numEvents":7,"numAffected":5,"numAtRisk":13},{"groupId":"EG002","numEvents":24,"numAffected":21,"numAtRisk":46},{"groupId":"EG003","numEvents":40,"numAffected":28,"numAtRisk":52}]},{"term":"Oesophagitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 11","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":9},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13},{"groupId":"EG002","numEvents":23,"numAffected":19,"numAtRisk":46},{"groupId":"EG003","numEvents":26,"numAffected":21,"numAtRisk":52}]},{"term":"Stomatitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 11","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":9},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":46},{"groupId":"EG003","numEvents":4,"numAffected":3,"numAtRisk":52}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 11","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":9},{"groupId":"EG001","numEvents":3,"numAffected":2,"numAtRisk":13},{"groupId":"EG002","numEvents":13,"numAffected":8,"numAtRisk":46},{"groupId":"EG003","numEvents":24,"numAffected":17,"numAtRisk":52}]},{"term":"Asthenia","organSystem":"General disorders","sourceVocabulary":"MedDRA 11","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG002","numEvents":4,"numAffected":4,"numAtRisk":46},{"groupId":"EG003","numEvents":8,"numAffected":7,"numAtRisk":52}]},{"term":"Breakthrough pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 11","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":46},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":52}]},{"term":"Chest pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 11","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG002","numEvents":7,"numAffected":7,"numAtRisk":46},{"groupId":"EG003","numEvents":11,"numAffected":7,"numAtRisk":52}]},{"term":"Chills","organSystem":"General disorders","sourceVocabulary":"MedDRA 11","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG002","numEvents":6,"numAffected":3,"numAtRisk":46},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":52}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA 11","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":6,"numAtRisk":9},{"groupId":"EG001","numEvents":8,"numAffected":7,"numAtRisk":13},{"groupId":"EG002","numEvents":32,"numAffected":26,"numAtRisk":46},{"groupId":"EG003","numEvents":36,"numAffected":27,"numAtRisk":52}]},{"term":"Mucosal inflammation","organSystem":"General disorders","sourceVocabulary":"MedDRA 11","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG002","numEvents":6,"numAffected":6,"numAtRisk":46},{"groupId":"EG003","numEvents":6,"numAffected":6,"numAtRisk":52}]},{"term":"Oedema","organSystem":"General disorders","sourceVocabulary":"MedDRA 11","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":46},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":52}]},{"term":"Pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 11","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":13},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":46},{"groupId":"EG003","numEvents":4,"numAffected":3,"numAtRisk":52}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA 11","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":9},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13},{"groupId":"EG002","numEvents":6,"numAffected":4,"numAtRisk":46},{"groupId":"EG003","numEvents":5,"numAffected":5,"numAtRisk":52}]},{"term":"Hypoalbuminaemia","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 11","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG002","numEvents":3,"numAffected":3,"numAtRisk":46},{"groupId":"EG003","numEvents":6,"numAffected":4,"numAtRisk":52}]},{"term":"Bronchitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 11","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG002","numEvents":5,"numAffected":4,"numAtRisk":46},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":52}]},{"term":"Candidiasis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 11","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":46},{"groupId":"EG003","numEvents":5,"numAffected":4,"numAtRisk":52}]},{"term":"Localised infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 11","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":46},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":52}]},{"term":"Oral candidiasis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 11","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":46},{"groupId":"EG003","numEvents":4,"numAffected":4,"numAtRisk":52}]},{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 11","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13},{"groupId":"EG002","numEvents":3,"numAffected":3,"numAtRisk":46},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":52}]},{"term":"Upper respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 11","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG002","numEvents":6,"numAffected":5,"numAtRisk":46},{"groupId":"EG003","numEvents":3,"numAffected":3,"numAtRisk":52}]},{"term":"Urinary tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 11","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG002","numEvents":3,"numAffected":3,"numAtRisk":46},{"groupId":"EG003","numEvents":3,"numAffected":3,"numAtRisk":52}]},{"term":"Radiation oesophagitis","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 11","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":46},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":52}]},{"term":"Radiation skin injury","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 11","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":3,"numAffected":1,"numAtRisk":13},{"groupId":"EG002","numEvents":5,"numAffected":5,"numAtRisk":46},{"groupId":"EG003","numEvents":3,"numAffected":3,"numAtRisk":52}]},{"term":"Alanine aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 11","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG002","numEvents":3,"numAffected":3,"numAtRisk":46},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":52}]},{"term":"Aspartate aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 11","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG002","numEvents":3,"numAffected":3,"numAtRisk":46},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":52}]},{"term":"Blood creatinine","organSystem":"Investigations","sourceVocabulary":"MedDRA 11","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":46},{"groupId":"EG003","numEvents":4,"numAffected":3,"numAtRisk":52}]},{"term":"Blood lactate dehydrogenase","organSystem":"Investigations","sourceVocabulary":"MedDRA 11","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":13},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":46},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":52}]},{"term":"Creatinine renal clearance decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 11","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":46},{"groupId":"EG003","numEvents":3,"numAffected":3,"numAtRisk":52}]},{"term":"Gamma-glutamyltransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 11","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":46},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":52}]},{"term":"Haemoglobin","organSystem":"Investigations","sourceVocabulary":"MedDRA 11","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG002","numEvents":3,"numAffected":3,"numAtRisk":46},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":52}]},{"term":"Haemoglobin decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 11","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG002","numEvents":12,"numAffected":8,"numAtRisk":46},{"groupId":"EG003","numEvents":7,"numAffected":4,"numAtRisk":52}]},{"term":"Neutrophil count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 11","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG002","numEvents":6,"numAffected":2,"numAtRisk":46},{"groupId":"EG003","numEvents":4,"numAffected":3,"numAtRisk":52}]},{"term":"Platelet count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 11","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG002","numEvents":9,"numAffected":4,"numAtRisk":46},{"groupId":"EG003","numEvents":4,"numAffected":3,"numAtRisk":52}]},{"term":"Weight decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 11","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":9},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13},{"groupId":"EG002","numEvents":13,"numAffected":13,"numAtRisk":46},{"groupId":"EG003","numEvents":9,"numAffected":9,"numAtRisk":52}]},{"term":"White blood cell count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 11","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":46},{"groupId":"EG003","numEvents":4,"numAffected":3,"numAtRisk":52}]},{"term":"Anorexia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 11","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":2,"numAtRisk":9},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":13},{"groupId":"EG002","numEvents":12,"numAffected":12,"numAtRisk":46},{"groupId":"EG003","numEvents":9,"numAffected":9,"numAtRisk":52}]},{"term":"Decreased appetite","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 11","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":3,"numAffected":2,"numAtRisk":13},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":46},{"groupId":"EG003","numEvents":4,"numAffected":3,"numAtRisk":52}]},{"term":"Dehydration","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 11","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13},{"groupId":"EG002","numEvents":10,"numAffected":10,"numAtRisk":46},{"groupId":"EG003","numEvents":8,"numAffected":8,"numAtRisk":52}]},{"term":"Hyperglycaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 11","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG002","numEvents":5,"numAffected":5,"numAtRisk":46},{"groupId":"EG003","numEvents":7,"numAffected":6,"numAtRisk":52}]},{"term":"Hyperkalaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 11","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":46},{"groupId":"EG003","numEvents":5,"numAffected":3,"numAtRisk":52}]},{"term":"Hypocalcaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 11","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":46},{"groupId":"EG003","numEvents":13,"numAffected":6,"numAtRisk":52}]},{"term":"Hypokalaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 11","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":13},{"groupId":"EG002","numEvents":16,"numAffected":10,"numAtRisk":46},{"groupId":"EG003","numEvents":12,"numAffected":8,"numAtRisk":52}]},{"term":"Hypomagnesaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 11","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG002","numEvents":3,"numAffected":3,"numAtRisk":46},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":52}]},{"term":"Hyponatraemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 11","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG002","numEvents":7,"numAffected":3,"numAtRisk":46},{"groupId":"EG003","numEvents":13,"numAffected":8,"numAtRisk":52}]},{"term":"Arthralgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 11","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG002","numEvents":4,"numAffected":4,"numAtRisk":46},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":52}]},{"term":"Back pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 11","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":13},{"groupId":"EG002","numEvents":5,"numAffected":5,"numAtRisk":46},{"groupId":"EG003","numEvents":5,"numAffected":5,"numAtRisk":52}]},{"term":"Muscular weakness","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 11","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG002","numEvents":4,"numAffected":4,"numAtRisk":46},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":52}]},{"term":"Musculoskeletal pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 11","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":46},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":52}]},{"term":"Musculoskeletal stiffness","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 11","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":46},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":52}]},{"term":"Myalgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 11","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":46},{"groupId":"EG003","numEvents":3,"numAffected":3,"numAtRisk":52}]},{"term":"Ageusia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 11","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":46},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":52}]},{"term":"Balance disorder","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 11","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":46},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":52}]},{"term":"Dizziness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 11","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":9},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":13},{"groupId":"EG002","numEvents":10,"numAffected":9,"numAtRisk":46},{"groupId":"EG003","numEvents":7,"numAffected":4,"numAtRisk":52}]},{"term":"Dysgeusia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 11","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":9},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13},{"groupId":"EG002","numEvents":5,"numAffected":5,"numAtRisk":46},{"groupId":"EG003","numEvents":6,"numAffected":5,"numAtRisk":52}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 11","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":9},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13},{"groupId":"EG002","numEvents":5,"numAffected":5,"numAtRisk":46},{"groupId":"EG003","numEvents":4,"numAffected":4,"numAtRisk":52}]},{"term":"Neuropathy peripheral","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 11","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG002","numEvents":3,"numAffected":3,"numAtRisk":46},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":52}]},{"term":"Paraesthesia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 11","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":46},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":52}]},{"term":"Peripheral motor neuropathy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 11","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":46},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":52}]},{"term":"Peripheral sensory neuropathy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 11","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":46},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":52}]},{"term":"Restless legs syndrome","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 11","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":46},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":52}]},{"term":"Tremor","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 11","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":46},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":52}]},{"term":"Anxiety","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 11","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG002","numEvents":6,"numAffected":6,"numAtRisk":46},{"groupId":"EG003","numEvents":6,"numAffected":6,"numAtRisk":52}]},{"term":"Depression","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 11","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":9},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13},{"groupId":"EG002","numEvents":7,"numAffected":6,"numAtRisk":46},{"groupId":"EG003","numEvents":6,"numAffected":6,"numAtRisk":52}]},{"term":"Insomnia","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 11","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":9},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13},{"groupId":"EG002","numEvents":11,"numAffected":11,"numAtRisk":46},{"groupId":"EG003","numEvents":9,"numAffected":9,"numAtRisk":52}]},{"term":"Dysuria","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 11","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":46},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":52}]},{"term":"Micturition urgency","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 11","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":46},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":52}]},{"term":"Cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 11","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":9},{"groupId":"EG001","numEvents":3,"numAffected":2,"numAtRisk":13},{"groupId":"EG002","numEvents":15,"numAffected":15,"numAtRisk":46},{"groupId":"EG003","numEvents":16,"numAffected":14,"numAtRisk":52}]},{"term":"Dysphonia","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 11","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":9},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":13},{"groupId":"EG002","numEvents":3,"numAffected":3,"numAtRisk":46},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":52}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 11","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":9},{"groupId":"EG001","numEvents":5,"numAffected":4,"numAtRisk":13},{"groupId":"EG002","numEvents":10,"numAffected":9,"numAtRisk":46},{"groupId":"EG003","numEvents":13,"numAffected":12,"numAtRisk":52}]},{"term":"Haemoptysis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 11","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG002","numEvents":3,"numAffected":3,"numAtRisk":46},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":52}]},{"term":"Hiccups","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 11","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":46},{"groupId":"EG003","numEvents":7,"numAffected":5,"numAtRisk":52}]},{"term":"Hypoxia","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 11","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":46},{"groupId":"EG003","numEvents":4,"numAffected":4,"numAtRisk":52}]},{"term":"Oropharyngeal pain","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 11","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13},{"groupId":"EG002","numEvents":4,"numAffected":3,"numAtRisk":46},{"groupId":"EG003","numEvents":7,"numAffected":7,"numAtRisk":52}]},{"term":"Pleural effusion","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 11","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":46},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":52}]},{"term":"Rhinitis allergic","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 11","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":46},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":52}]},{"term":"Wheezing","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 11","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG002","numEvents":3,"numAffected":3,"numAtRisk":46},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":52}]},{"term":"Alopecia","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 11","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":13},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":46},{"groupId":"EG003","numEvents":3,"numAffected":3,"numAtRisk":52}]},{"term":"Dermatitis","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 11","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":46},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":52}]},{"term":"Dermatitis bullous","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 11","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":46},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":52}]},{"term":"Dry skin","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 11","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG002","numEvents":3,"numAffected":3,"numAtRisk":46},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":52}]},{"term":"Hyperhidrosis","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 11","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":2,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":46},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":52}]},{"term":"Night sweats","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 11","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":9},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":46},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":52}]},{"term":"Pruritus","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 11","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":46},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":52}]},{"term":"Rash","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 11","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":9},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":13},{"groupId":"EG002","numEvents":3,"numAffected":3,"numAtRisk":46},{"groupId":"EG003","numEvents":4,"numAffected":4,"numAtRisk":52}]},{"term":"Rash erythematous","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 11","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":46},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":52}]},{"term":"Hypertension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 11","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG002","numEvents":3,"numAffected":3,"numAtRisk":46},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":52}]},{"term":"Hypotension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 11","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":9},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13},{"groupId":"EG002","numEvents":3,"numAffected":3,"numAtRisk":46},{"groupId":"EG003","numEvents":5,"numAffected":4,"numAtRisk":52}]},{"term":"Orthostatic hypotension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 11","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":46},{"groupId":"EG003","numEvents":3,"numAffected":3,"numAtRisk":52}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"GT60","restrictiveAgreement":true},"pointOfContact":{"title":"Chief Medical Officer","organization":"Eli Lilly and Company","phone":"800-545-5979"}}},"derivedSection":{"miscInfoModule":{"versionHolder":"2025-12-17"},"conditionBrowseModule":{"meshes":[{"id":"D002289","term":"Carcinoma, Non-Small-Cell Lung"}],"ancestors":[{"id":"D002283","term":"Carcinoma, Bronchogenic"},{"id":"D001984","term":"Bronchial Neoplasms"},{"id":"D008175","term":"Lung Neoplasms"},{"id":"D012142","term":"Respiratory Tract Neoplasms"},{"id":"D013899","term":"Thoracic Neoplasms"},{"id":"D009371","term":"Neoplasms by Site"},{"id":"D009369","term":"Neoplasms"},{"id":"D008171","term":"Lung Diseases"},{"id":"D012140","term":"Respiratory Tract Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"D000068437","term":"Pemetrexed"},{"id":"D002945","term":"Cisplatin"},{"id":"D016190","term":"Carboplatin"},{"id":"D011878","term":"Radiotherapy"}],"ancestors":[{"id":"D006147","term":"Guanine"},{"id":"D007042","term":"Hypoxanthines"},{"id":"D011688","term":"Purinones"},{"id":"D011687","term":"Purines"},{"id":"D006574","term":"Heterocyclic Compounds, 2-Ring"},{"id":"D000072471","term":"Heterocyclic Compounds, Fused-Ring"},{"id":"D006571","term":"Heterocyclic Compounds"},{"id":"D005971","term":"Glutamates"},{"id":"D024342","term":"Amino Acids, Acidic"},{"id":"D000596","term":"Amino Acids"},{"id":"D000602","term":"Amino Acids, Peptides, and Proteins"},{"id":"D000600","term":"Amino Acids, Dicarboxylic"},{"id":"D017606","term":"Chlorine Compounds"},{"id":"D007287","term":"Inorganic Chemicals"},{"id":"D017672","term":"Nitrogen Compounds"},{"id":"D017671","term":"Platinum Compounds"},{"id":"D056831","term":"Coordination Complexes"},{"id":"D009930","term":"Organic Chemicals"},{"id":"D013812","term":"Therapeutics"}]}},"hasResults":true}